L2S AB, a life science company specialized in interactive cognitive behavioural therapy, has signed an international agreement with Pfizer.
L2S, Learning 2 Sleep AB, is a Minc company based in Malmö with three part-owners. The company was founded in 2010 and provides services based on CBT treatment of sleeping disorders. One of the first services from L2S according to the new agreement will be within sleeping. One of the services will, according to L2S, be promoted by one of Sweden’s leading corporate health service companies. The new service will replace all other therapeutic treatment of sleeping disorders, states L2S.
The partnership between Pfizer and L2S is based on a licensing agreement. “We are convinced that as a strong partner to Pfizer, we can contribute to creating good development possibilities both nationally and internationally,” said Peter Boye, founder of L2S.
